peizhi zhou

Dr. peizhi zhou


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
LLLiang Lyu
Liang Lyu
YJYong Jiang
Yong Jiang
WMWeichao Ma
Weichao Ma
HLHaiyan Li
Haiyan Li
XLXiaoling Liu
Xiaoling Liu
SYSenlin Yin
Senlin Yin

31 July 2019 in Endocrine
Verified
Journal Article
Closed access
PDF file
LLLiang Lv
Liang Lv
YJYong Jiang
Yong Jiang
SYSenlin Yin
Senlin Yin
YHYu Hu
Yu Hu
CCCheng Chen
Cheng Chen
PZpeizhi zhou
peizhi zhou

26 July 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CCCheng Chen
Cheng Chen
YHYu Hu
Yu Hu
LLLiang Lyu
Liang Lyu
SYSenlin Yin
Senlin Yin
YYYang Yu
Yang Yu
PZpeizhi zhou
peizhi zhou
Comprehensive investigations on the incidence and prognosis of pituitary tumors are still lacking. The present study aims to summarize the incidence, demographics, and survival outcome of pituitary adenoma on a population-based level. This study includes all pituitary adenomas reported in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2016 in the United States. Extensive clinical and demographic characteristics were extracted and submitted to group comparisons. The standardized incidence rate was calculated and stratified by year at diagnosis, age/sex and age/treatment groups. The Kaplan–Meier analysis and multivariable regressions were performed to identify the factors associated with overall survival. A total of 47,180 pituitary tumors were identified, including 47,030 typical adenomas, 111 uncertain behavior pituitary adenomas, and 39 pituitary carcinomas. The overall standardized incidence rate was 4.8 cases per 100,000 person-years and the annual incidence rate continually trended upwards, with a peak seen in 2015. We noticed a bimodal age-related distribution in females and a unimodal distribution in males. In the multivariate regression analysis, the factors associated with prolonged survival included typical adenoma, younger age, and smaller tumor size. Whereas, black and male patients had worse overall survival. Our study provides a reliable estimate on the incidence of pituitary adenoma and confirms that the annual standardized incidence rate is increasing. Pituitary adenomas have a satisfactory long-term prognosis and age, tumor size, and tumor subtypes are related to overall survival. Though statistically significant, our inferential findings should be constrained within the limitations of SEER database.

15 June 2022
Verified
Journal Article
Closed access
CZChuanhong Zhong
Chuanhong Zhong
LPLilei Peng
Lilei Peng
BTBei Tao
Bei Tao
SYSenlin Yin
Senlin Yin
LLLiang Lyu
Liang Lyu
PZpeizhi zhou
peizhi zhou

18 January 2022 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
LLLiang Lyu
Liang Lyu
HLHaiyan Li
Haiyan Li
CCCheng Chen
Cheng Chen
YYYang Yu
Yang Yu
LWLi Wang
Li Wang
PZpeizhi zhou
peizhi zhou
Non-functional pituitary adenomas (NFPAs) are one of the most prevalent pituitary adenoma subtypes. The lack of reliable screening approach for NFPAs for the insidious clinical course usually leads to delays in medical therapy and consequently worse prognosis. Hence, we employed a sequence cohort (patient: control, 6:2) and a validation cohort (patient: control, 22:8) to develop a serum exosomal miRNA profile-based method for NFPA screening and prognosis prediction. We found that a total of 1,395 kinds of human miRNA were detected. Compared with healthy donors, 18 up-regulated and 36 down-regulated miRNAs showed significant expression alterations in NFPA patients. Target genes of differentially expressed miRNAs are mainly enriched in axonogenesis and cancer-associated terms. After validation, hsa-miR-486-5p, hsa-miR-151a-5p, hsa-miR-652-3p_R+1, and hsa-miR-1180-3p were promising biomarkers for NFPA, in which miR-486-5p was the most competent one. After a median of 33 months of prospective follow-up, exosomal hsa-miR-486-5p also was an efficient predictive biomarker for progression or relapse of NFPAs. By protein-protein interaction network construction of hsa-miR-486-5p targeted genes, the core modules revealed a high possibility that exosomal hsa-miR-486-5p regulated tumor progression by epigenetic regulation of MAPK signaling pathways. In conclusion, exosomal hsa-miR-486-5p, hsa-miR-151a-5p, hsa-miR-652-3p_R+1, and hsa-miR-1180-3p are candidate biomarkers for diagnosis and screening of NFPAs. More importantly, prospective follow-up reveals that hsa-miR-486-5p can be regarded as a significant predictor for prognosis of NFPAs.

20 January 2022 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
JLJianguo Li
Jianguo Li
LLLiang Lyu
Liang Lyu
CCCheng Chen
Cheng Chen
SYSenlin Yin
Senlin Yin
SJShu Jiang
Shu Jiang
PZpeizhi zhou
peizhi zhou